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2,3-dioxygenase in the development of depressive symptoms. We highlight how combining basic immune
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speciﬁc biomarkers and in developing immunotherapeutic treatment strategies that take individual variability
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The immune system consists of biological structures and processes
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defence mechanism characterized by increased blood ﬂow and recruit-
ment of innate immune cells to the site of injury. The link between
increased inﬂammation and depression was detected in the early
1990s (Maes et al., 1990; Maes et al., 1991), leading to the formulation
of the macrophage hypothesis of depression (also known as the
cytokine hypothesis of depression (Maes, 1995; Smith, 1991). This
model proposes that external and internal stressors trigger depressive
behaviour by elevating the production of proinﬂammatory cytokines
interleukin-1 (IL-1) and IL-6, as well as activating cell-mediated immu-
nity. More recently, an abundance of observational, experimental and
clinical evidence has emerged to suggest that the activation of innate
immune mechanisms, especially proinﬂammatory cytokines IL-1, IL-6
and tumor necrosis factor alpha (TNF-α), as well as C-reactive protein
(CRP), may contribute to the initiation and progression of psychiatric
diseases, such as depression (Capuron et al., 2003; Dowlati et al.,
2010; Gimeno et al., 2009; Howren et al., 2009; Kivimaki et al., 2014;
Liu et al., 2012; Raison et al., 2010; Valkanova et al., 2013). Several re-
cent publications have focused on these associations (Capuron and
Miller, 2011; Dantzer et al., 2008; Haroon et al., 2012; Jones and
Thomsen, 2013; McCusker and Kelley, 2013; Mills et al., 2013;
Mitchell and Goldstein, 2014; Quan and Banks, 2007; Raedler, 2011;
Rivest, 2009) and while the majority of this evidence involves pro-
inﬂammatory cytokines and CRP, changes in the function and numbers
of innate immune cells, namely natural killer (NK) cells, have also been
examined.
In addition to increased innate immune responses, activation of cell-
mediated adaptive immunity has been described in depressed patients.
This includes increased CD4+/CD8+T cell ratios, i.e. higher percentage
of CD4+ T cells and a lower percentage of CD8+ T suppressor cells
(Darko et al., 1988;Maes et al., 1992b; Tondo et al., 1988). Furthermore,
elevated numbers and a higher proportion of activated T cells bearing
activation markers CD2+ CD25+, CD3+ CD25+, HLA-DR+ (Maes
et al., 1992a), higher blood levels of IL-2R (Liu et al., 2012) and increased
number of B cell subsets (Maes et al., 1992c; Robertson et al., 2005) have
been detected in patients with major depressive disorder compared
with controls. On the other hand, reduced proliferative response of T
cells to mitogen in subjects with depression has been shown in a
meta-analysis (Zorrilla et al., 2001), suggesting that depression may
be associated with concurrent activation and suppression of immune
responses.
In this review, we present a model on co-operative mechanisms
between innate and adaptive immunity in the periphery and central
nervous system (CNS), and the potential role of such molecules in the
pathology of depressive mood. We discuss the interrelations between
cytokines, T cells, NK cells, inﬂammasomes, microglia, indoleamine-
2,3-dioxygenase (IDO) and neurotoxic vs. neurotrophic factors, all of
which have been suggested to contribute to the initiation and progres-
sion of depressive symptoms. Finally, we discuss how novel methodol-
ogies, such as the ‘omics’ technologies, might represent the next step in
uncovering the relations between altered immune function and
depressive disorders.
2. Evidence on immune–brain relations
In animal experiments, peripherally administered proinﬂammatory
cytokines IL-1β and TNF-α as well as lipopolysaccharide (LPS) and syn-
thetic compound mimicking viral infection (Poly (I:C)) have induced
‘sickness behaviour’ characterized by lethargy, depression, anxiety,
loss of appetite, and sleepiness (Dantzer, 2001; Gibney et al., 2013).
This response is thought to be caused by pro-inﬂammatory cytokines
temporarily expressed in the brain during infection (Dantzer et al.,
2008). In humans, injections with LPS (Reichenberg et al., 2001) or
administration of typhoid vaccine (Harrison et al., 2009) have been
shown to be related to an increased production of proinﬂammatory
cytokines and subsequent decline in mood, while pre-treatment withan antidepressant drug, citalopram, a selective serotonin reuptake in-
hibitor, has reduced LPS-induced depressive symptoms in healthy sub-
jects (Hannestad et al., 2011).
Information on brain-immune relations in the CNS has also been
acquired using positron emission tomography (PET) to measure the
density of translocator protein (TSPO), a microglia-derived protein
showing increased expression during neuroinﬂammation. In one PET
study, TSPOVT (volume distribution) was elevated in patients with
more severe forms of depression (Setiawan et al., 2015). Another
study failed to ﬁnd differences in the levels of [11C]PBR28VT, a ligand
binding to TSPO, between individuals with mild-to-moderate depres-
sion and control subjects (Hannestad et al., 2013). These results suggest
that neuroinﬂammatory activation via TSPO may only be observed in
more severe forms of depression, but more research is needed to
conﬁrm these relations. Furthermore, cross-sectional design of these
studies cannot inform about whether inﬂammation is a cause of a
consequence of depression.
Additional evidence for immune–brain associations has emerged
from clinical studies. For example, approximately 20–50% of cancer
and hepatitis C patients treated with injections of interferon-α (IFN-
α) have been estimated to develop clinically signiﬁcant depression
(Raison et al., 2005). IFN-α-induced depression has been associated
with elevated serum levels of sIL-2r, TNF-α, and IL-6 (Wichers et al.,
2007). Interestingly, there is also evidence to suggest that this IFN-α
induced depression is responsive to conventional antidepressant
treatments, an observation consistent with the hypothesized shared
pathways between inﬂammation and idiopathic major depression
(Capuron et al., 2002; Musselman et al., 2001).
Epidemiological studies provide further support for the association
between altered inﬂammatory proﬁle and depression. A recent cumula-
tive meta-analysis on 31 cross-sectional studies on IL-6 and 20 studies
on CRP showed a robust association between increased levels of these
two inﬂammatory markers and major depression, although the
relations between TNF-α and major depression were not conﬁrmed in
a total of in 31 studies due to extensive heterogeneity in study-speciﬁc
effect estimates and inconsistencies between subgroups (Haapakoski
et al., 2015). No consistent evidence support a link between IL-1β and
depression (14 studies), which may in part be related to the very low
concentrations of this cytokine in peripheral blood and a lack reliable
detection methods. At least two meta-analyses support the existence
of reduced proliferative activity of lymphocytes and lowered NK cell ac-
tivity in depression (Herbert and Cohen, 1993; Zorrilla et al., 2001).
Furthermore, increased number of leukocytes has been associated
with depression (Zorrilla et al., 2001) whereas evidence regarding the
number of different subsets of T cells, B cells, NK cells and NKT cells in
depression is inconclusive. These ﬁndings suggest speciﬁcity in the
associations of various inﬂammatory markers and depression but
several methodological issues may also contribute to the observed
inconsistencies, including the heterogeneity of depressive disorder
and imprecise measurement of some subsets of immune cells.
Longitudinal analyses of observational data provide inconsistent
information on the temporal order between CRP, proinﬂammatory
cytokines and depression. In the Whitehall II study, for example, high
levels of CRP and IL-6 at baselinehave been associatedwith an increased
risk of future cognitive symptoms of depression whereas baseline
symptoms of depression did not predict the level of CRP or IL-6 at
follow-up (Gimeno et al., 2009). This ﬁnding is in agreement with a
study showing that elevated levels of IL-6 in childhood are associated
with an increased risk of depression in young adulthood (Khandaker
et al., 2014). Chronically elevated inﬂammation in the development of
psychiatric symptoms is supported by data from Whitehall II study
showing repeated measurements of IL-6 dose-dependently increasing
the risk of future common mental disorder (Kivimaki et al., 2014). On
the other hand, at least one study has found that somatic-vegetative
symptoms of depression predicted 6-year change in IL-6 levels whereas
baseline levels of neither IL-6 nor CRP were predictors of change in
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other study, depressive symptoms predicted CRP levels in adolescents
and young adults (Copeland et al., 2012). These results indicate the pos-
sibility of bidirectional association between inﬂammation and depres-
sion and that the strength and direction of the association may be
dependent on speciﬁc depressive symptom clusters, type of immune
markers measured and/or population characteristics such as age, pa-
tient type (communal vs. clinical sample) and comorbid disorders.
More prospective investigations including repeat measurements of
both immune function and depression in different patient groups and
with various immune markers are needed to ascertain the extent to
which inﬂammation is a cause and a consequence of depression.
3. A model of immune–brain interactions in mood regulation
Fig. 1 illustrates a simpliﬁed model where interactions between in-
nate and adaptive immune mechanisms and neuronal and hormonal
connections, both in the periphery and the brain, provide excitatory
and suppressive signals leading to the activation of multiple brain re-
gions involved in mood regulation. Immune response can be initiated
by external exposure to bacterial or viral components, such as lipopoly-
saccharide (LPS) or synthetic dsRNA Poly (I:C) or via psychological or
physiological stress reaction, vigorous exercise, inﬂammation, trauma
or tissue injury. In the periphery, different pattern recognition receptors
(PRRs, e.g. Toll like receptors [TLRs] and C-lectin like receptors [CLRs])
are expressed in the outer membranes of the skin or mucosa and inFig. 1. Suggested links of innate and adaptive immunity and neuroendocrine circuitswith the de
matory cytokines, chemokines and acute phase proteins may be induced by external exposu
exercise, inﬂammation, trauma or tissue injury. Cross talk between innate and adaptive immun
in the periphery and the central nervous systemmayhave a profound effect on behavioural alte
related to speciﬁc immune–brain associations (references list and explanation for abbreviationthe cells of innate immunity such as NK cells and dendritic cells (DCs)
(referred also as antigen presenting cells; APCs) providing the ﬁrst con-
tact of the micro-organism to the body's cells (Janeway andMedzhitov,
2002). Binding of ligand to its speciﬁc receptor leads to the activation
of signalling transduction cascades and to the production of pro-
inﬂammatory cytokines, IL-1β, TNF-α and IFN, chemokines and acute
phase proteins. Furthermore, stress response activates mechanisms
within the sympathetic nervous system (SNS) and the hypothalamo-
pituitary-adrenal (HPA) axis associated with increased production of
catecholamines, such as norepinephrine (NE) and epinephrine (E),
and the glucocorticoid cortisol in the blood. Neuropeptide Y (NPY) is
also released from the sympathetic nerve terminals in response to
exposure to stressors.
Proinﬂammatory cytokines IL-1, IL-6 and TNF released in response to
a stressor activate the HPA axis and induce the release of endogenous
glucocorticoids which, in turn, suppress HPA activity and innate im-
mune responses. Constant communication and feedback mechanism
between corticotrophin-releasing hormone (CRH), adrenocorticotropic
hormone (ACTH), cortisol and catecholamines E and NE contribute to
the regulation of hormonal and immunological responses in the periph-
ery and the CNS and to physiological response to stress (Black, 2002;
Ulrich-Lai and Herman, 2009). The increased production of proinﬂam-
matory cytokines and immune intermediates is thought to lead to im-
pairments in glucocorticoid receptor signalling and glucocorticoid
resistance, conditions frequently observed in depressed patients (Pace
and Miller, 2009). Furthermore, E and NE have been shown to affectvelopment of depression. Activation of immune response and the production of proinﬂam-
re to bacterial or viral components or via psychological or physiological stress reaction,
e cells, inﬂammatory and endocrine signalling molecules and neuromodulatory processes
rations and the development of depression. Numbers in theﬁgure designate key references
s are provided in the Supplementary material).
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duction (Elenkov et al., 2000), supporting neuroendocrine communica-
tion between the immune system and the brain.
3.1. The bridge between innate and adaptive immunity in depression
Fig. 1 also shows that interactions between the innate and adaptive
immune systems in the periphery and the CNSmay result in stimulation
or suppression of T cells and NK cells, both phenomena being demon-
strated in depressed patients (Liu et al., 2012; Maes, 1995; Maes et al.,
1992a; Pavon et al., 2006; Robertson et al., 2005; Zorrilla et al., 2001).
In addition, there is evidence on altered Th1/Th2 cytokine and regulato-
ry T cell (Treg) balance in patientswithmajor depression (Li et al., 2010;
Pavon et al., 2006). In the periphery, DCs play a critical role inmediating
the communication between the innate and adaptive immunity by act-
ing as professional APCs, activating CD4+/CD8+ T cells and regulating
T lymphocyte function (Merad et al., 2013; Steinman, 2007). In the CNS,
pathogen-associated molecular patterns (PAMPs) or danger-associated
molecular patterns (DAMPs) regulate the production of pro-
inﬂammatory cytokines IL-1β, IL-6 and TNF-α and activation of T lym-
phocytes (Shastri et al., 2013). The availability of PRRs/PAMPs/DAMPs
and co-stimulatory molecules in CNS-resident cells and the overall na-
ture of the cytokine milieu provided by different APCs have been sug-
gested to serve as a bridge between innate and adaptive immune
cascades and as determinants of T cell differentiation (Steinman,
2007). There is also emerging evidence that NK cells contribute to
long-lasting “memory-like” functional alterations indicating that NK
cells may play an important role as a bridge between innate and adap-
tive immunity (Rolle et al., 2013).
Immune-inducing molecules can activate brain signalling via a vari-
ety of neural, humoral and cellularmechanisms. For example, cytokines
may enter into the brain parenchyma passively through the leaky
regions in the blood brain barrier (BBB) such as the choroid plexus
(CP), by using cytokine-speciﬁc transport molecules or by transmission
of cytokine signals via afferent vagus nerve ﬁbers (reviewed in
(Capuron andMiller, 2011; Dantzer, 2009; Dantzer et al., 2008). Mature
T lymphocytes are able to enter the CNS via several routes during condi-
tions of stress and in disease states (Ransohoff et al., 2003). Immune
cells can be found at least in three anatomical sites in the brain in nor-
mal physiological and in disease states, that is, in CSF, meninges and
brain parenchyma (Wilson et al., 2010).
In murine models, the trafﬁc of T cells to the CP following exposure
to a psychological stress, and immunization with CNS-speciﬁc peptide
activating self-reactive T cells have been reported to modify depressive
behaviour; this effect seems to be accompanied by a restoration of the
levels of brain-derived neurotrophic factor (BDNF) to the pre-stress
level (Lewitus et al., 2008; Lewitus et al., 2009) and the development
of new neurons (neurogenesis) in the hippocampus (Lewitus et al.,
2009). The importance of lymphocytes in protecting the host from psy-
chological stress reaction is supported by recent study showing less
anxiety, reduced pro-inﬂammatory cytokine levels and increased
neuroprotective proﬁle in mice receiving lymphocytes from defeated
donors compared with those receiving cells from unstressed donors
(Brachman et al., 2015). Furthermore, decreased circulating BDNF levels
in patients with depression (Molendijk et al., 2014) and positive associ-
ations between elevated BDNF and IL-6 levels and between BDNF and
leukocyte counts in patients with major depression (Patas et al., 2014)
suggest that interactions between T and B cells, cytokines and
neurotrophic factors, such as BDNF, may be associated with the neuro-
pathology of depression.
Deﬁcits in NK cell function have been hypothesized to be associated
with the pathology of depression (Herbert and Cohen, 1993; Zorrilla
et al., 2001). Reduced NK cell activity in combination with an increased
serum IL-6 level is indicative of the co-existence of suppression and ac-
tivation of innate immune responses in depression (Blume et al., 2011;
Pike and Irwin, 2006). Deﬁcits in NK-cell activity have also beenassociated with symptoms frequently associated with mood disorders,
such as sleep disturbances (Irwin et al., 1994; Irwin et al., 1996). In line
with this concept, sleep restriction has increased lymphocyte activation,
elevated the numbers of B cells as well as increased the production of
proinﬂammatory cytokines IL-1β, IL-6, IL-17 and CRP and at the same
time reduced the number of NK cells (van Leeuwen et al., 2009). Further-
more, acute psychophysiological stress has been associatedwith blunted
levels of cortisol, increased levels of IL-6 and greater percentage of Treg
cells (Ronaldson et al., 2015).
Exposure to acute stress reaction such as sleep disturbances, a phe-
nomenon commonly found in melancholic depression, leads to blunted
activation and number of APCs (DCs and NK cells) and increased proin-
ﬂammatory cytokines and CRP. Consequently, the number of T and B cells
may temporarily increase to prepare the body to ﬁght against “intruder”.
When the stress reaction sustains, as in chronic depression, thesemecha-
nisms may becomemaladaptive and detrimental; i.e. reduced availabili-
ty of messenger cells for T cell activation may result in lowered
stimulatory activity of leukocytes and down regulation of body's defence
mechanisms. Furthermore, lowered numbers of Treg cells in depressed
patients (Li et al., 2010) suggest an imbalance between positive and neg-
ative regulatorymechanisms after chronic exposure to stressor. Especial-
ly in vulnerable individuals, these reactions may be associated with
increased susceptibility to physical and physiological harm and worsen-
ing of depressive symptoms.
3.2. Role of microglia and inﬂammasomes
In the CNS, microglia cells residing in the brain parenchyma repre-
sent the chief innate immune cells capable of mediating innate and
adaptive immune responses via PRR-mediated recognition (Rivest,
2009) (Fig. 1). Microglial cells can engulf and clear damaged cell mate-
rial and phagocytose neurons undergoing apoptosis (Nimmerjahn et al.,
2005). Microglia also has an important role in regulating synaptic prun-
ing during brain development (Paolicelli et al., 2011). PRRs expressed in
microglia cells, astrocytes and CNS-derived macrophages act as sensors
for foreign antigens by stimulating the migration of immune cells, e.g.
macrophages, neutrophils, T cells and B cells to the site of injury and
by activating astrocytes and adjacent glial cells (Beynon and Walker,
2012; Walsh et al., 2014).
The intensity and nature of the effects mediated by inﬂammation-
activated microglia may differ depending on the identity and combina-
tion of activated TLRs (Rosenberger et al., 2014). For example, endoge-
nous DAMP produced in response to non-physiological cell death,
damage or stress reaction are able to activate innate immune cells via
TLRmediated signalling and induce the formation of the inﬂammasome
consisting of multiprotein complexes formed by NLR family members
NLRP1, NLRP3, and NLRC4 (Bianchi, 2007; Leemans et al., 2011). These
danger signals are thought to function synergistically with PAMPs to
alert the immune system to rapidly mobilize the release of their intra-
cellular contents into the extracellular space and to provide the initial
defence against pathogens and damage control of tissue injury (Kono
and Rock, 2008). Initiation of an inﬂammatory response and the forma-
tion of the inﬂammasome enable the activation of proinﬂammatory
caspases, mainly caspase-1 and subsequently, increased release of
pro-inﬂammatory cytokines (Walsh et al., 2014). A recent review has
proposed an integrated role of glucocorticoids and NLRP3-mediated
inﬂammation in response to stress (Frank et al., 2013). According to
this model, the effects of glucocorticoids on TLRs and inﬂammasomes
prime and facilitate the central and peripheral inﬂammatory immune
responses via immune effectors (e.g. microglia) during stress (ﬁght/
ﬂight) response in situations of exogenous injury.
Preclinical models suggest a role for immune-sensingmicroglia cells
in the development of depressive-like behaviour (Fenn et al., 2014;
Kreisel et al., 2014). This is consistent with the possibility that
inﬂammasome-mediated caspase-1 activation and induction in the pro-
duction of cytokines IL-1β and IL-18 in microglia cells are an important
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disorders associated with elevated inﬂammation. In support of this
concept, increased gene expression of NLRP3 and caspase-1 in
the mononuclear blood cells and elevated serum levels of IL-1β and
IL-18 have been found in patients with major depression (Alcocer-
Gomez et al., 2014). Furthermore, NLRP3 has been associated with
LPS-induced depression in a murine model (Zhang et al., 2014),
suggesting a role of inﬂammasomes and Nod-like receptor signalling
pathways in the immunity–depression relationship.
3.3. Role of IDO, glutamate and neurotoxic catabolites
Recently, the role of enzyme IDO in the immunity-depression link-
age has received increasing attention (Chen, 2011). Activation of IDO
is induced by the production of proinﬂammatory cytokines as a
response to physiological or psychological stress. IDO is the enzyme
that catalyzes the rate-limiting step in the degradation of tryptophan
(TRP), an essential amino acid in the conversion of serotonin into
kynurenine (KYN). KYN is further metabolized into tryptophan catabo-
lites (TRYCATs) such as neuroprotective kynurenine acid (KA) and neu-
rotoxic quinolinic acid (QUIN). QUIN, primarily produced by brain
microglial cells, is an agonist of the glutamatergic N-methyl-D-
aspartate (NMDA) receptor; therefore, activation of IDO leads to a re-
duced synthesis of serotonin as well as to the overactivation of gluta-
mate receptors in the brain (these processes have been described in
detail by Dantzer et al. (2008) and in (Muller and Schwarz, 2007). Con-
sequently, sustained release of proinﬂammatory cytokines bymicroglial
cells, called neuroinﬂammation, may promote neuronal damage and
neuronal death, similar to decreased neurogenesis and reduced serum
levels of BDNF and increased glutamate release or inhibition of gluta-
mate uptake (Pav et al., 2008; Tilleux andHermans, 2007). Several tryp-
tophanmetabolites and glutamate are neurotoxic and this may result in
neuronal damage and cellular loss especially in the hippocampus, po-
tentially increasing the risk of neuropsychiatric disorders (Maes et al.,
2011; Myint et al., 2012).
The role of neurotoxic metabolites in immune-modulated neuro-
transmission is supported by studies showing upregulated levels of pe-
ripheral and central KYN and increased QUIN in the CNS, correlating
with IFN-α induced depression (Raison et al., 2010). Further evidence
of the role of IDO and KYN in depression comes from preclinical studies
showing an induction of depression-like behaviour after administration
of L-kynurenine (L-KYN) (O'Connor et al., 2009). Furthermore, in some
studies depressed patients have had an increased density of QUIN-
positive cells (Steiner et al., 2011) increased glutamate (Hashimoto
et al., 2007) and deﬁcits in glutamate transporter molecules in the
brain cortex (Choudary et al., 2005). Despite reduced levels of peripher-
al TRP, the central levels of TRP do not appear to be affected by IFN-a
treatment (Raison et al., 2010), raising the possibility that neurotoxic
end-products rather than serotonin play a role in the pathology of
depression.
Microarray analyses of post-mortem frontal cortex provide some
evidence on increased inﬂammatory, apoptotic, and oxidative stress in
patients with major depressive disorder (Shelton et al., 2011). For
example, the serum kyurenic acid (KA)/quinolinic acid (QUIN) ratio, a
putative neuroprotective index, tended to be lower in patients with
major depression compared to those free of depression and this ratio
has been found to be associatedwith higher hippocampal and amygdala
volumes (Savitz et al., 2015a; Savitz et al., 2015b). However, the evi-
dence suggesting morphological alterations in depression is relatively
modest and the overall change in neuronal loss in depression has been
suggested to be rare (Lucassen et al., 2001) requiring exposure to
prolonged severe stress before changes become detectable (Lucassen
et al., 2006). Meta-analytic reviews have found discrepancies regarding
the volumetric differences in various brain areas in depressed versus
control subjects with, for example, lower hippocampal volume in
depression being detectable onlywhenmeasured as a discrete structurein patients with longstanding illness (Campbell et al., 2004) or in pa-
tients with more than one previous disease episode (McKinnon et al.,
2009). In addition, a meta-analytic review concluded that although
late-life depression appears to be associated with minor volume
reductions in hippocampus in the summary evidence, this association
remains uncertain as there was heterogeneity between studies with
many studies reporting negative ﬁndings (Sexton et al., 2013). These re-
sults indicate that while there is some evidence supporting the involve-
ment of neurotoxic catabolites KYN and QUIN in the pathology of
depression, more research is needed to conclude whether activation of
IDO and involvement of neurodegenerative substances are associated
with hippocampal atrophy, reduced neurogenesis and neuronal cell
death in depressive individuals.
3.4. Associations between inﬂammatory and neuroendocrine mechanisms
in depression
Extensive evidence shows an association of inﬂammation with HPA
axis malfunction and bi-directional associations between immune and
neuroendocrine systems (Maes et al., 1993; Maes et al., 2009; Raison
and Miller, 2003; Tafet and Bernardini, 2003; Zunszain et al., 2011).
Alterations in both cellular (Th1) and humoral (Th2) arms of adaptive
immunity have been linked to theHPA axis function; i.e. glucocorticoids
suppress the production of Th1 type cytokine IL-12 but upregulate the
production of IL-4 by Th2 cells (Blotta et al., 1997; Franchimont et al.,
2000). Conversely, cytokines are capable of stimulating the HPA axis di-
rectly, as indicated by the enhanced release of ACTH and glucocorticoids
in patients developing depressive symptoms after IFN-α–treatment
(Capuron et al., 2003). Cytokines are thought to be involved in the im-
paired feedbackmechanisms and glucocorticoid resistance via their sig-
nalling pathways, such as nuclear factor-κB (NF-κB,) signal transducers
and activators of transcription, all of which have been found to inhibit
GR function (Pace et al., 2007). However, considerable variation in the
degree of HPA activation in depressed patients exists and some patients
display no evidence of HPA overactivity (Marques-Deak et al., 2007;
Strickland et al., 2002; Swaab et al., 2005; Watson et al., 2002). This
may partly reﬂect the heterogeneity of depressive disorders, with the
role of HPA axis dysfunction being more prominent in the more severe
forms of the disease, such as in melancholic and psychotic depression
(Lamers et al., 2013; Nelson and Davis, 1997; O'Keane et al., 2012). In
addition, it has been suggested that interactions between inﬂammatory
molecules, glucocorticoids and other HPA axis mechanisms, such as
renin–angiotensin–aldosterone system (RAAS), nutritional gut hor-
mone glucagon-like peptide 1 and growth hormones,may be associated
with the development of depressive symptoms and contribute to the
high prevalence of immune-related chronic disorders, such as diabetes,
in groups of depressive patients (Mahajan et al., 2004; Murck et al.,
2012; Numakawa et al., 2013).
3.5. Summary of evidence
Preclinical and clinical evidence shows both activation and suppres-
sion of immune responses in depressed patients.While an abundance of
evidence supports increased levels of proinﬂammatory cytokines and
acute phase proteins in depression, important questions still remain
regarding the role of altered adaptive immunity and the co-operation
between innate and adaptive immunemechanisms in depressive disor-
ders. Among themany fundamental questions that remain unanswered
are the “protective autoimmunity”mediated by different, yet unknown
subsets of CNS autoreactive T cells (Miller, 2010; Rook et al., 2011).
These T cells have shown neuroprotective and anti-depressive effects
in preclinical models, indicating that T cells may possess some, yet
unknown, role in maintaining homeostatic functions in depression.
Furthermore, the speciﬁc role of different T cell subsets, e.g. regulatory
T cells and CD4+/CD8+ T cells in the pathology of depression are yet
to be established.
Fig. 2. Examples of basic immunological methodologies and high-throughput “omics”
techniques for the investigation of immune mechanisms in depressive patients using
peripheral blood. Abbreviations: PBMC: peripheral blood mononuclear cell; RT-PCR:
real-time polymerase chain reaction; ELISA: enzyme-linked immunosorbent assay.
68 R. Haapakoski et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 66 (2016) 63–72It has been speculated that increased neuronal activity triggers
innate and adaptive immune cells, vascular cells and neurons in the
CNS leading to pathological neuroinﬂammation after persistent
exposure to the stressors (Xanthos and Sandkuhler, 2014). Increasing ev-
idence also postulates the activation of microglia and the inﬂammasome-
mediated pathways in the pathology of depression (Setiawan et al.,
2015). In particular, activation of NLRP inﬂammasomes and increased
proinﬂammatory cytokines, including IL-1β, is suggested to be involved
in the maladaptive changes in the CNS during depressive episode.
Another hypothesis linked to immune-induced depression, besides the
well-known serotonin deﬁciency, is an increased activation of IDO and
accumulation of glutamate and tryptophan catabolites such as KYN.
KYN is known to possess many immunomodulatory effects on innate
and adaptive immune cells, such as a blockade of T and NK cell prolifera-
tion and induction of T cell apoptosis (Fallarino et al., 2003; Terness et al.,
2002). Since peripheral L-KYN and 3-hydroxy-L-kynurenine (3-HK) can
enter the CNS via the blood brain barrier (Vecsei et al., 2013), central
and/or peripheral activation of IDO and the formation of neurotoxic
catabolites in response to increased inﬂammatory activity may account
for the adverse innate and adaptive immune effects and the perpetuation
of other central immune-induced changes, such as serotonin deﬁciency
associated with depression (Dantzer et al., 2011). Reduced production
of factors linked to neuronal plasticity and cell growth, such as BDNF,
may further increase the risk for depressive symptoms in susceptible
individuals (Bocchio-Chiavetto et al., 2010).
During the acute phase of stress, proinﬂammatory cytokines, acute
phase proteins, chemokines and other inﬂammatory mediators and
the activation status of APCs and NK cells increase. In addition, the
immune-induced processes such as formation of inﬂammasomes and
increased production IDO are activated via CNS resident astrocytes,
macrophages ormicroglia. Chronic elevations in proinﬂammatory cyto-
kines, and imbalance in pro- and anti-inﬂammatory cytokines, changes
in the number and activity of T and B cells, development of glucocorticoid
resistance and the accumulation of cell-toxic and neurodegenerative ele-
ments may lead maladaptive changes when the body's natural coping
mechanisms fail to maintain homeostasis and respond efﬁciently to ex-
ternal stressors. Depending on comorbid diseases, overall health status
and other risk factors these pathological processesmay induceworsening
of physiological symptoms and accelerate the development of depression
in certain individuals. In the future, the challenge lies in identifying sub-
groups of depressed patients with increased inﬂammatory-induced
symptoms, who could beneﬁt from immunomodulatory anti-depressive
therapies.
4. Omics technologies in depression research
Despite substantial research efforts, the exact role of immunological
status in depression pathology has remained elusive. To advance this
research, a number of immunological techniques, ranking from basic
laboratory techniques to more sophisticated sample analysis involving
omics techniques (proteomics, transcriptomics, metabolomics, geno-
mics and epigenomics) may be used to study the integrated networks
of genes, proteins and biochemical interactions in the periphery and in
the CNS (Fig. 2). Combining immunological data with neuropsychiatric
tests and clinical assessments may provide a better outlook on the
hormonal and structural alterations associated with depression.
Omics technologies could, for example, aid in the identiﬁcation of
new, depression-speciﬁc biomarkers which may be applied for several
purposes, including improvement of diagnosis, predicting the course
of disease and designing more personalized treatment methods for
depression (Domenici et al., 2010; Schwarz and Bahn, 2008; Uher
et al., 2012). Biomarker studies may use two different approaches:
(a) A hypothesis-driven method with pre-selected biomarkers and
(b) a hypothesis-free, data-driven method.
Inﬂammatory molecules, in particular proinﬂammatory cytokines,
provide an example of hypothesis-driven biomarkers with respect tovarious depression models, including the vascular depression concept
as the inﬂammatory markers have been related to an increased risk
for future cardiovascular diseases (Engstrom et al., 2004; Galea and
Brough, 2013; Hingorani and Casas, 2012; Ridker et al., 2000) and
depression (Gimeno et al., 2009; Kivimaki et al., 2014; Lanquillon
et al., 2000). For example, elevated levels of inﬂammatory biomarkers
CRP, IL-1β and TNF-α have been linked to poor antidepressant treat-
ment response in depressed patients (Cattaneo et al., 2013; Uher et al.,
2014), indicating that inﬂammatorymoleculesmay have role as predic-
tive biomarkers in depression treatment, for example in estimating the
efﬁcacy or suitability of a treatment before the trial.
Recent technological advances have triggered many new research
projects utilizing data-driven proﬁling assays where no prior knowl-
edge of genes involved in the process is required. Omics technologies
such as mass spectrometry, microarray or sequencing methods may
be especially beneﬁcial in the search for biomarkers for the identiﬁca-
tion of disease-speciﬁc markers for depression (Ditzen et al., 2012;
Filiou et al., 2012; Sunde, 2010). This approach allows researchers to in-
vestigate thousands of potential gene transcripts of unknown origin and
to identify gene expression changes in depressed patients. Search
for biomarkers for depression using peripheral blood has attracted
increasing interest in depression research, as it shares over 80% of the
transcriptomewith brain and is more easily accessible for research pur-
poses (Liew et al., 2006).With this respect, proteomics and transcripto-
mics technologies have already been utilized in recent studies
comparing the differences in protein and mRNA expression proﬁles in
the blood of depressed patients versus healthy controls (Lee et al.,
2015; Pajer et al., 2012; Xu et al., 2012). Distinct protein signatures
have also been identiﬁed in post-mortem brain tissues of depressed
patients (Martins-de-Souza et al., 2012).
Heterogeneity of themajor depressive disorder phenotype has been
recognized as one of the factors resulting in a poor replication of
candidate genes for major depression (Bosker et al., 2011). General
lack of understanding of the underlying neurobiology of psychiatric
disorders is further hindering the identiﬁcation of disease-speciﬁc
biomarkers (Murck et al., 2015). Several studies have shown that the
role of inﬂammation and HPA axis dysfunction varies depending on the
subtype of depression (Anisman et al., 1999; Lamers et al., 2013;
Rothermundt et al., 2001; Spanemberg et al., 2014; Yoon et al., 2012).
Furthermore, depressive symptoms characterizing sickness behaviour
i.e. lack of energy, sleep problems and changes in appetite, were recently
Fig. 3. Schematic diagram showing how large-scale immunological, hormonal and neuronal characterization and personalized biological proﬁling of depressed subjectsmay advantage the
development of individualized treatment methods and the identiﬁcation of new biomarkers for depressive disorder.
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(Jokela et al., 2015). These results suggest that the extent to which in-
ﬂammation contributes to depression may be speciﬁc to the symptoms
and/or to the biological correlates associated with the pathology of
depression, indicating that certain type of treatment does not ﬁt for all
depressive patients. Also, many people with elevated circulating inﬂam-
matory markers and/or cortisol levels do not develop depression,
suggesting that other factor(s) including stressful life events, childhood
trauma, genetic predisposition, comorbid chronic diseases or lifestyle
factors may play important role in the development of depressive
symptoms.
How can omicsmethodologies help us to unravel the speciﬁc biolog-
ical mechanisms behind the disorder in different subgroups of
depressed patients and how this information may be translated into
clinical practice in the future? Firstly, using conventional laboratory
techniques, identiﬁcation of proteins and cells being affected in different
subgroups of depressed patients could be used to prescreen the poten-
tial depression-speciﬁc biomarkers (Fig. 3). Secondly,more comprehen-
sive analyses of these markers could be exploited using omics
methodologies to assess the immunological and neurohormonal proﬁle,
including expression, function and interactions between different in-
nate and adaptive immune cells, cytokines, chemokines, costimulatory
molecules, growth factors and neurohormonal mediators in the serum
and/or tissues of depressed patients to identify subgroups of patients
with speciﬁc biochemical signatures. Ultimately, this approach could
be employed for the development depression-speciﬁc biomarkers and
personalized treatment methods related to the pathological mecha-
nisms associated with the disorder.
5. Conclusions and future directions
Future investigations would beneﬁt from approaches exploring
the role of the entire immune system and its relation with different
neuroendocrine alterations relevant to depressive disorders. In this
respect, research strategies aimed at untangling the integrative roleof inﬂammatory cytokines, different subsets of T cells and
neuroinﬂammatory factors in depression will be required. The combi-
nation of different technologies and the identiﬁcation of different
genes, proteins and metabolites related to depression neuropathology
may lead to a number of breakthroughs such as the following:
1) Characterization of new biochemical pathways and neurobiological
targets related to depression as well as increased understanding of
their relevance for disease outcome.
2) Development of new potential biomarkers and new therapeutic
applications.
3) Better understanding of individual variation in the outcome of anti-
depressant medication before treatment trials using predictive
biomarkers.
Multi-disciplinary cooperation and utilization of a wide array of new
technological platforms are vital in clarifying the role of immune alter-
ations and exploring innovative therapeutic applications for depressive
disorders.
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